Effect of TSHAC on Human Cytochrome P450 Activity, and Transport Mediated by P-Glycoprotein |
Im, Yelim
(College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Kim, Yang-Weon (Department of Emergency Medicine, Busan Paik Hospital, Inje University College of Medicine) Song, Im-Sook (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University) Joo, Jeongmin (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University) Shin, Jung-Hoon (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University) Wu, Zhexue (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University) Lee, Hye Suk (College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea) Park, Ki Hun (Division of Applied Life Science, Gyeongsang National University) Liu, Kwang-Hyeon (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University) |
1 | Zvyaga, T., S. Y. Chang, C. Chen, Z. Yang, R. Vuppugalla, J. Hurley, et al. 2012. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: Focus on cytochrome P450 2C19. Drug Metab. Dispos. 40: 1698-1711. DOI |
2 | Lin, J. H. and M. Yamazaki. 2003. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin. Pharmacokinet. 42: 59-98. DOI ScienceOn |
3 | Liow, J. S., S. Lu, J. A. McCarron, J. Hong, J. L. Musachio, V. W. Pike, et al. 2007. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. Synapse 61: 96-105. DOI ScienceOn |
4 | Liu, K. H., M. J. Kim, B. H. Jeon, J. H. Shon, I. J. Cha, K. H. Cho, et al. 2006. Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba. J. Clin. Pharm. Ther. 31: 83-91. DOI ScienceOn |
5 | Liu, K. H., M. J. Kim, J. H. Shon, Y. S. Moon, S. Y. Seol, W. Kang, et al. 2005. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica 35: 27-38. DOI ScienceOn |
6 | Markowitz, J. S. and C. L. Devine. 1997. Drug interaction potential of fluoxetine, sertraline, and paroxetine in four state psychiatric hospital populations. Ther. Drug Monit. 19: 244-245. DOI ScienceOn |
7 | Muzi, M., D. A. Mankoff, J. M. Link, S. Shoner, A. C. Collier, L. Sasongko, et al. 2009. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: Studies of healthy humans. J. Nucl. Med. 50: 1267-1275. DOI ScienceOn |
8 | Nakamura, K., N. Ariyoshi, T. Iwatsubo, Y. Fukunaga, S. Higuchi, K. Itoh, et al. 2005. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol. Pharm. Bull. 28: 882-885. DOI ScienceOn |
9 | Rieth, H. and N. Sauerbrey. 1989. [Interaction studies with fluconazole, a new triazole antifungal drug]. Wien. Med. Wochenschr. 139: 370-374. |
10 | Seo, K. A., H. Kim, H. Y. Ku, H. J. Ahn, S. J. Park, S. K. Bae, et al. 2008. The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. Chem. Biol. Interact. 174: 141-146. DOI ScienceOn |
11 | Shin, J. G., J. Y. Park, M. J. Kim, J. H. Shon, Y. R. Yoon, I. J. Cha, et al. 2002. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: Mechanism of drug interaction between TCAs and phenytoin. Drug Metab. Dispos. 30: 1102-1107. DOI ScienceOn |
12 | Shin, J. G., N. Soukhova, and D. A. Flockhart. 1999. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metab. Dispos. 27: 1078-1084. |
13 | Srinivas, N. R. 2008. The drug-drug interaction potential of rifampicin. Clin. Ther. 30: 1932-1933. DOI ScienceOn |
14 | Tachibana, T., M. Kato, J. Takano, and Y. Sugiyama. 2010. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr. Drug Metab. 11: 762-777. DOI ScienceOn |
15 | Yoon, Y. J. and K. H. Liu. 2011. Potential of hydroxyebastine and terfenadine alcohol to inhibit the human cytochrome P450 2J2 isoform. J. Korean Soc. Appl. Biol. Chem. 54: 659-666. |
16 | Corriu, C., M. Feletou, E. Canet, and P. M. Vanhoutte. 1996. Inhibitors of the cytochrome P450-mono-oxygenase and endothelium-dependent hyperpolarizations in the guinea-pig isolated carotid artery. Br. J. Pharmacol. 117: 607-610. DOI ScienceOn |
17 | Giacomini, K. M., S. M. Huang, D. J. Tweedie, L. Z. Benet, K. L. Brouwer, X. Chu, et al. 2010. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9: 215-236. DOI ScienceOn |
18 | Dravid, P. V. and R. F. Frye. 2008. Determination of Ndesethylamodiaquine by hydrophilic interaction liquid chromatography with tandem mass spectrometry: Application to in vitro drug metabolism studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 863: 129-134. DOI ScienceOn |
19 | Franklin, M. R. and L. B. Hathaway. 2008. 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) revisited: Comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol. Drug Metab. Dispos. 36: 2539-2546. DOI ScienceOn |
20 | Gan, J., W. Chen, H. Shen, L. Gao, Y. Hong, Y. Tian, et al. 2010. Repaglinide-gemfibrozil drug interaction: Inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br. J. Clin. Pharmacol. 70: 870-880. DOI ScienceOn |
21 | Guengerich, F. P. 1997. Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol. 43: 7-35. |
22 | Han, H. K. 2011. Role of transporters in drug interactions. Arch. Pharm. Res. 34: 1865-1877. DOI ScienceOn |
23 | He, F., H. C. Bi, Z. Y. Xie, Z. Zuo, J. K. Li, X. Li, et al. 2007. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: Application to high-throughput inhibition screening of terpenoids. Rapid Commun. Mass Spectrom. 21: 635-643. DOI ScienceOn |
24 | Ji, H. Y., K. H. Liu, H. Lee, S. R. Im, H. J. Shim, M. Son, et al. 2011. Corydaline inhibits multiple cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 16: 6591-6602. DOI |
25 | Lee, S. A., H. W. Ryu, Y. M. Kim, S. Choi, M. J. Lee, T. K. Kwak, et al. 2009. Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 49: 1316-1325. DOI ScienceOn |
26 | Kaeser, B., H. Zandt, F. Bour, E. Zwanziger, C. Schmitt, and X. Zhang. 2009. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. Antimicrob. Agents Chemother. 53: 609-614. DOI ScienceOn |
27 | Kim, M. J., H. Kim, I. J. Cha, J. S. Park, J. H. Shon, K. H. Liu, et al. 2005. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19: 2651-2658. DOI ScienceOn |
28 | Lee, S. A., M. S. Lee, H. W. Ryu, T. K. Kwak, H. Kim, M. Kang, et al. 2011. Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib. Cancer Biol. Ther. 11: 330-336. DOI ScienceOn |
29 | Ambudkar, S. V., C. Kimchi-Sarfaty, Z. E. Sauna, and M. M. Gottesman. 2003. P-glycoprotein: From genomics to mechanism. Oncogene 22: 7468-7485. DOI ScienceOn |